Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Journal of Medical Economics
|
December 17, 2016
Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic
Darya B Rose, Dave Nellesen, Maureen P Neary, et al.
Journal of Managed Care & Specialty Pharmacy
|
July 19, 2021
Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
Pallavi Patwardhan, David Proudman, Jeffrey Allen, et al.
Journal of Managed Care Pharmacy : JMCP
|
October 26, 2013
A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation
Dave Nellesen, Kimberly Yee, Anita Chawla, et al.
Advances in Therapy
|
February 14, 2022
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib
David Proudman, Dave Nellesen, Deepshekhar Gupta, et al.
Pediatric Blood & Cancer
|
January 17, 2022
Burden of central nervous system complications in sickle cell disease: A systematic review and meta-analysis
Soyon Lee, Sedge Lucas, David Proudman, et al.
JAMA Network Open
|
November 17, 2020
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan
David Proudman, Aaron Miller, Dave Nellesen, et al.
Postgraduate Medicine
|
July 3, 2013
Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade
Dave Nellesen, Anita Chawla, Debora L Oh, et al.
Journal of Medical Economics
|
October 3, 2024
Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations
David Proudman, Urvi Desai, Dumingu Aparna Gomes, et al.
Oncotarget
|
May 16, 2022
Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes
David G Proudman, Deepshekhar Gupta, Dave Nellesen, et al.
Orphanet Journal of Rare Diseases
|
November 3, 2021
A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease
Ahmar U Zaidi, Alexander K Glaros, Soyon Lee, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Journal of Medical Economics
|
December 17, 2016
Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic
Darya B Rose, Dave Nellesen, Maureen P Neary, et al.
Journal of Managed Care & Specialty Pharmacy
|
July 19, 2021
Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
Pallavi Patwardhan, David Proudman, Jeffrey Allen, et al.
Journal of Managed Care Pharmacy : JMCP
|
October 26, 2013
A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation
Dave Nellesen, Kimberly Yee, Anita Chawla, et al.
Advances in Therapy
|
February 14, 2022
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib
David Proudman, Dave Nellesen, Deepshekhar Gupta, et al.
Pediatric Blood & Cancer
|
January 17, 2022
Burden of central nervous system complications in sickle cell disease: A systematic review and meta-analysis
Soyon Lee, Sedge Lucas, David Proudman, et al.
JAMA Network Open
|
November 17, 2020
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan
David Proudman, Aaron Miller, Dave Nellesen, et al.
Postgraduate Medicine
|
July 3, 2013
Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade
Dave Nellesen, Anita Chawla, Debora L Oh, et al.
Journal of Medical Economics
|
October 3, 2024
Public sector replacement of privately funded pharmaceutical R&D: cost and efficiency considerations
David Proudman, Urvi Desai, Dumingu Aparna Gomes, et al.
Oncotarget
|
May 16, 2022
Tazemetostat in relapsed/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000-101 trial outcomes
David G Proudman, Deepshekhar Gupta, Dave Nellesen, et al.
Orphanet Journal of Rare Diseases
|
November 3, 2021
A systematic literature review of frequency of vaso-occlusive crises in sickle cell disease
Ahmar U Zaidi, Alexander K Glaros, Soyon Lee, et al.
Page
of 2